Results 31 to 40 of about 980,977 (401)

Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis

open access: yesStem cell research & therapeutics, 2017
BackgroundOsteoarthritis (OA) is the most common joint disease worldwide. In the past decade, mesenchymal stem cells (MSCs) have been used widely for the treatment of OA.
Yu Zhu   +9 more
semanticscholar   +1 more source

Induced Stem Cells as a Novel Multiple Sclerosis Therapy. [PDF]

open access: yes, 2016
Stem cell replacement is providing hope for many degenerative diseases that lack effective therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. Transplantation of neural stem cells or
Guan, Yang-Tai   +3 more
core   +2 more sources

Pluripotency of Induced Pluripotent Stem Cells

open access: yesGenomics, Proteomics & Bioinformatics, 2013
Abstract Induced pluripotent stem (iPS) cells can be generated by forced expression of four pluripotency factors in somatic cells. This has received much attention in recent years since it may offer us a promising donor cell source for cell transplantation therapy. There has been great progress in iPS cell research in the past few years.
Feng, Chunjing   +2 more
openaire   +2 more sources

The alternative 3′ splice site of GPNMB may promote neuronal survival after neonatal hypoxic–ischemic encephalopathy injury

open access: yesIbrain, 2022
This study aimed to decipher the effect of glycoprotein nonmetastatic melanoma protein B (GPNMB) on neonatal hypoxic–ischemic encephalopathy (NHIE) and its potential molecular mechanism.
Guo‐Jiao Chen   +5 more
doaj   +1 more source

Non-human primate pluripotent stem cells for the preclinical testing of regenerative therapies

open access: yesNeural Regeneration Research, 2022
Non-human primates play a key role in the preclinical validation of pluripotent stem cell-based cell replacement therapies. Pluripotent stem cells used as advanced therapy medical products boost the possibility to regenerate tissues and organs affected ...
Ignacio Rodriguez-Polo, Rüdiger Behr
doaj   +1 more source

p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

open access: yesNature Medicine, 2018
CRISPR/Cas9 has revolutionized our ability to engineer genomes and conduct genome-wide screens in human cells1–3. Whereas some cell types are amenable to genome engineering, genomes of human pluripotent stem cells (hPSCs) have been difficult to engineer,
Robert J Ihry   +19 more
semanticscholar   +1 more source

Investigating the functionality of an OCT4-short response element in human induced pluripotent stem cells. [PDF]

open access: yes, 2016
Pluripotent stem cells offer great therapeutic promise for personalized treatment platforms for numerous injuries, disorders, and diseases. Octamer-binding transcription factor 4 (OCT4) is a key regulatory gene maintaining pluripotency and self-renewal ...
Awe, Jason P   +9 more
core   +3 more sources

Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells

open access: yesNature Biotechnology, 2020
Generation of pancreatic β cells from human pluripotent stem cells (hPSCs) holds promise as a cell replacement therapy for diabetes. In this study, we establish a link between the state of the actin cytoskeleton and the expression of pancreatic ...
N. Hogrebe   +4 more
semanticscholar   +1 more source

Generation of an isogenic iPSC line via CRISPR correction of the POMC:W84X mutation for monogenic obesity modeling

open access: yesStem Cell Research
We report the generation of a genetically corrected induced pluripotent stem cell (iPSC) line, BIHi261-A-1, derived from the patient-specific iPSC line BIHi261-A carrying a homozygous truncating mutation in the POMC gene (POMC:W84X). This mutation causes
Katarzyna A. Ludwik   +6 more
doaj   +1 more source

Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons? [PDF]

open access: yes, 2013
Heart failure after myocardial infarction is the leading cause of mortality and morbidity worldwide. Existing medical and interventional therapies can only reduce the loss of cardiomyocytes during myocardial infarction but are unable to replenish the ...
Liao, S, Tse, HF
core   +2 more sources

Home - About - Disclaimer - Privacy